Psoriatic Arthritis a Review Journal of German Anne Journal of German Society of Dermatology

• Loading metrics

Open Admission

Peer-reviewed

Research Article

Patient Preferences for Handling of Psoriasis with Biologicals: A Discrete Selection Experiment

• Christian Kromer,
• Marthe-Lisa Schaarschmidt,
• Astrid Schmieder,
• Raphael Herr,
• Sergij Goerdt,
• Wiebke One thousand. Peitsch

x

• Published: June nine, 2015
• https://doi.org/x.1371/periodical.pone.0129120

Figures

Abstract

Treatment dissatisfaction and non-adherence are common amongst patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. Even so, patients are more satisfied with biologicals than with other treatments. The aim of our written report was to assess patient preferences for treatment of psoriasis with biologicals by using computer-based conjoint analysis. Biologicals canonical for psoriasis in Deutschland were decomposed into outcome (probability of fifty% and 90% comeback, fourth dimension until response, sustainability of success, probability of mild and astringent adverse events (AE), probability of American College of Rheumatology (ACR) 20 response) and process attributes (treatment location, frequency, duration and delivery method). Impact of sociodemographic and socioeconomic characteristics and affliction severity on Relative Importance Scores (RIS) of each attribute was assessed with analyses of variance, postal service hoc tests, and multivariate regression. Averaged across the accomplice of 200 participants with moderate-to-severe psoriasis, preferences were highest for fugitive astringent AE (RIS = 17.iii), followed by 90% comeback (RIS = 14.0) and avoiding balmy AE (RIS = 10.5). Process attributes reached intermediate RIS (eight.ii–8.viii). Men were more concerned near efficacy than women (l% improvement: RIS = 6.9 vs. 9.5, p = 0.008; β = -0.191, p = 0.011 in multivariate models; ninety% improvement: RIS = 12.ane vs. xv.four, p = 0.002; β = -0.197, p = 0.009). Older participants judged the probability of 50% and 90% comeback less relevant than younger ones (50% improvement: Pearson'due south Correlation (PC) = -0.161, p = 0.022; β = -0.219, p = 0.017; 90% improvement: PC = -0.155, p = 0.028; β = -0.264, p = 0.004) simply worried more about severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). In summary, participants with moderate-to-severe psoriasis were most interested in safety of biologicals, followed by efficacy, but preferences varied with sociodemographic characteristics and working status. Based on this knowledge, physicians should place preferences of each individual patient during shared decision-making in order to optimize treatment satisfaction, adherence and outcome.

Commendation: Kromer C, Schaarschmidt M-Fifty, Schmieder A, Herr R, Goerdt Due south, Peitsch WK (2015) Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Pick Experiment. PLoS ONE 10(vi): e0129120. https://doi.org/ten.1371/journal.pone.0129120

Bookish Editor: Reza Khodarahmi, Kermanshah University of Medical Sciences, Iran

Received: November 30, 2014; Accustomed: May 5, 2015; Published: June 9, 2015

Copyright: © 2015 Kromer et al. This is an open access article distributed nether the terms of the Creative Eatables Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Data Availability: All relevant data are inside the paper.

Funding: The study was funded by the young scientists' plan of the German network "Health Services Enquiry Baden-Württemberg" of the Ministry of Scientific discipline, Research and Arts in collaboration with the Ministry of Employment and Social Club, Family, Women and Senior Citizens, Baden-Württemberg (grant to Marthe-Lisa Schaarschmidt). In improver, the authors admit the financial support of the Deutsche Forschungsgemeinschaft and the University of Heidelberg within the funding program Open Admission Publishing.

Competing interests: Mr. Kromer obtained honoraria from Janssen-Cilag. Dr. Schaarschmidt conducted clinical trials for Abbvie, Eli Lilly, Merck, Novartis and UCB Pharma; obtained honoraria from Janssen-Cilag; and received financial back up for participation in conferences from Abbvie, ALK-Abello, Biogen Inc., Janssen-Cilag and MSD. Dr. Schmieder conducted clinical trials for Abbvie and Pfizer and obtained back up for conferences from Celgene, Abbvie, Janssen-Cilag and Pfizer. Prof. Goerdt obtained honoraria as Editor-in-Main of the Periodical of the German Dermatological Society (JDDG) and support for conferences from Abbvie, ALK-Abello, Alma Lasers, ARC Lasers, Asclepion, BMS, GSK, Janssen-Cilag, Fifty'Oreal, LEO Pharma, Medac, Merck, MSD, Novartis, P&M Cosmetics, Pfizer and Roche. Prof. Peitsch served as investigator for Abbvie, Eli Lilly, Janssen-Cilag, Merck, Novartis, Pfizer and UCB Pharma; was member of an informational board of MSD and Novartis; obtained honoraria from ALK-Abello, Abbvie, Janssen-Cilag, MSD and Novartis; and received support for conferences from Abbvie, ALK-Abello, Alma Lasers, ARC Lasers, Asclepion, BMS, GSK, Janssen-Cilag, L'Oreal, LEO Pharma, Medac, Merck, MSD, Novartis, P&Grand Cosmetics, Pfizer and Roche. Mr. Herr has no conflict of interest to declare. The written report presented here was non supported by pharmaceutical companies. The authors' competing interests do not alter their adherence to PLOS ONE policies on sharing data and materials.

Introduction

Psoriasis is one of the most common chronic-inflammatory diseases of the skin and joints with high impact on emotional and social well-being, life form and occupational career [one]. The well-being of affected patients is not just influenced by the psoriasis itself, but also by its management [ii,iii]. To identify an effective treatment with reasonable risks and costs, physicians ofttimes chose a stepwise approach starting with topical and phototherapy, escalating to traditional systemic medication and ending with biologicals [4].

Biologicals approved as second-line treatments for refractory psoriasis in Germany consist of the TNF antagonists etanercept, adalimumab and infliximab and the interleukin 12/23 adversary ustekinumab. All of them have a favourable benefit-risk profile [4,5] but they possess some differences in response rates, rapidity of action and sustainability [6–8]. Chances of achieving reduction of the Psoriasis Surface area and Severity Index (PASI) by l, 75 or 90% (PASI 50, 75 or ninety response rates) are higher for infliximab, ustekinumab and adalimumab than for etanercept [6]. Onset of activity is fastest for infliximab, followed past ustekinumab and adalimumab [8]. Both TNF antagonists and ustekinumab are approved for psoriatic arthritis, but American College of Rheumatology (ACR) 20 response rates may exist somewhat higher for TNF antagonists [9,ten]. Moreover, the treatment process, i.due east., the mode and frequency of application of each biological is different. Etanercept, adalimumab and ustekinumab are administered subcutaneously (etanercept and adalimumab with a pen or a prefilled syringe, ustekinumab with a prefilled syringe). Infliximab is given intravenously as infusion. Etanercept has to be applied one time to twice weekly, adalimumab every two weeks, infliximab every eight and ustekinumab every 12 weeks.

Patients with psoriasis receiving biologicals are on boilerplate very satisfied with their handling, whereas patients with other treatments report higher dissatisfaction, oft caused by discordance between handling requirements and individual needs [two]. This contributes to high rates of non-adherence [2,11,12]. One way to improve handling satisfaction, adherence and thereby event is integration of patients' preferences into shared controlling. Patients' preferences for psoriasis treatments were assessed in a number of studies and with dissimilar techniques, some of which originally stem from marketing research [xiii–17]. We previously performed conjoint assay (CA), a method imitating the trade-off process typical of clinical controlling, to arm-twist patients' preferences for psoriasis treatments [18–21]. We showed that when faced with all kinds of treatment options including topical therapy, phototherapy, traditional systemic therapy and biologicals patients prioritize an efficient and convenient outpatient therapy [18]. The aim of the present report was to identify patients' preferences for outcome and process attributes of biologicals and to report the impact of sociodemographic and socioeconomic factors and affliction severity on these preferences.

Materials and Methods

Report participants

Preferences of patients with moderate-to-astringent psoriasis for the attributes of biologicals were assessed in an open cantankerous-exclusive study at the Department of Dermatology of the University Medical Center Mannheim, Frg. All patients presenting to our outpatient department with moderate-to-astringent psoriasis were pre-screened to determine their eligibility to participate in the written report. Every eligible patient was asked to participate. Participants who had provided written informed consent were carefully examined and checked for inclusion and exclusion criteria. Inclusion criteria were age ≥xviii years and moderate-to-severe psoriasis according to the criteria of the Commission for Medicinal Products for Human Use (CMPH), i.east., PASI≥10 in the class of the disease, involvement of head, palms or plantar surfaces, or psoriatic arthritis according to Classification of Psoriatic Arthritis (CASPAR) criteria with any pare involvement [22]. Diagnosis of psoriasis was based on clinical exam, combined with histology if the clinical diagnosis was questionable. Both patients with and without current antipsoriatic treatment were eligible for participation. Exclusion criteria were other diagnoses than moderate-to-severe psoriasis and inability to complete the survey due to difficulties with the German or incapacity to understand CA exercises (i.east., failing to respond exercises with unambiguous scenarios presented for control). The study was performed according to the principles of the Declaration of Helsinki and approved by the Ethics Commission of the Medical Faculty Mannheim (Ethics Approving 2009-329E-MA, 22 October 2009; Subpoena 27 September 2012).

Information collection

Participants were assigned an identification code to access a computerized survey before clinical consultation. The first part contained information on sociodemographic characteristics (age [in years], gender and partnership [living with or without a partner]) and socioeconomic characteristics (working condition [not working (including homemakers and retirees), working function-time, or working total-time] and cyberspace monthly household income [<1500 €, 1500-<3000 €, or ≥3000 €]) as well as the Dermatology Life Quality Index (DLQI).

In the second part, participants' preferences for treatment of psoriasis with biologicals were explored using CA, generated and evaluated basically equally described [18]. Seven cardinal outcome attributes (probability of fifty% improvement, probability of 90% improvement, time until response, sustainability of success, probability of mild adverse events (AE), probability of severe AE, and probability of ACR 20 response) and four process attributes (treatment location, frequency, duration, and delivery method) were selected (Table 1). Literature research including randomized controlled trials, guidelines, reviews and meta-analyses was performed to identify four realistic levels for each aspect that reflected characteristics of TNF antagonists and ustekinumab as closely as possible (e.g., [4–ten; 23–26]). Attributes were assigned to two groups, each with six attributes, to forestall information overload. Treatment elapsing was included into both groups to enable same-scaled comparison beyond all attributes. The two attributes describing efficacy (probability of fifty% and 90% comeback) were presented in different groups. The probability of ninety% comeback was depicted every bit chance of near consummate clearance. Examples of discrete choice scenarios with attributes of group 1 and group 2 are provided in Table ii. The CA exercises did not contain a cost aspect, because handling costs for biologicals are unremarkably covered past health insurance in Frg.

Participants were confronted with hypothetical treatment scenarios, designed by utilizing CBC/HB feature of commercially available CA software (http://www.sawtoothsoftware.com). This software created all possible combinations of attribute levels per group and randomly selected twelve pairs of scenarios of each group for each respondent by using a random-orthogonal method. In each experiment, respondents had to cull their preferred option with higher net utility. Three fixed experiments with 1 pick being superior in every attribute were presented to each participant for command.

PASI was recorded by 2 investigators (C.Yard. and K.-L.South.). Office-worth utilities for each attribute level were computed using logit regression, with positive values indicating high utility and negative values representing disutility. The range between the highest and the lowest office-worth utility within one aspect was used to summate the attribute's Relative Importance Score (RIS) as fraction of one attribute'due south range beyond the sum of all ranges. To compare results between attributes of group one and 2, attribute importance was translated into 1 list by matching the relative importance of treatment duration. Logarithmic transformations (Log_ten; for PASI, DLQI, probability of l% comeback, time until response, probability of ACR xx response, treatment frequency, elapsing, and commitment method) and foursquare root transformations (for probability of 90% improvement, sustainability of success, probability of mild and astringent AE, and treatment location) were practical to obtain normal distribution of the variables.

SPSS software was used for subgroup analyses. Associations of RIS with categorical variables were analysed by ANOVA (analysis of variance). Mail service hoc tests with Bonferroni correction were performed in cases of more than two subgroups. Pearson'southward Correlations (PC) were used for continuous factors. For sensitivity reasons, analyses were repeated using untransformed variables with non-parametric tests (Kruskal-Wallis Test for ANOVAs and Spearman'south rho for correlations). Significance was causeless at p≤0.05.

Regression analysis

Multivariate linear regression analysis was performed to estimate independent associations between participants' characteristics and RIS. Eleven models were created including age, gender, partnership, working status, DLQI, and PASI as independent variables and each aspect'south RIS as dependent variable. As monthly income did not significantly impact RIS according to descriptive analyses, this variable was non taken into business relationship for the models. Standardized regression coeffients (β) were assigned to each independent variable, indicating the amount of modify in RIS when varying i of the variables while belongings the others constant.

Results

239 patients were asked to participate; 210 met study criteria and provided written informed consent. Out of these, 10 had to be excluded, 9 because of difficulties with the High german and i due to disability empathize the CA exercises. 200 participants completed the survey (57.5% male, mean age: 50.8 years; for farther characteristics see Tabular array 3). The vast bulk (95.5%) came for a follow-up visit, and 99% currently received antipsoriatic treatment. 18.5% of the participants (n = 37) were treated exclusively with topical therapy, 58% (n = 116) with topical therapy in combination with another treatment modality, x% (due north = 20) with phototherapy, 37.v% (n = 75) with traditional systemic antipsoriatic medication and 43.5% (n = 87) with biologicals at the fourth dimension of data collection. Therefore the mean PASI was relatively low (three.4, range: 0–26.7). The mean DLQI was 6.2 (range: 0–30), respective to moderate affliction-related life quality impairment.

Patients' preferences averaged across the study sample

The attribute regarded as most important in the whole study collective was probability of severe AE (RIS = 17.3), followed past probability of 90% improvement (RIS = 14.0) and probability of mild AE (RIS = 10.five). Time until response (RIS = 4.5), sustainability of success (RIS = five.2) and probability of ACR twenty response (RIS = six.ii) were rated less important. All process attributes reached RIS betwixt 8.2 and 8.8 (Fig 1).

Fig 1. Relative Importance Scores (RIS) averaged across the study cohort.

The probability of astringent AE was evaluated equally most important (RIS = 17.3), followed by the probability of xc% improvement (RIS = xiv.0). Time until response (RIS = 4.5) and sustainability of the therapeutic success (RIS = 5.2) were least relevant. Bars: Means with standard deviations.

https://doi.org/10.1371/periodical.pone.0129120.g001

Impact of sociodemographic and socioeconomic characteristics, PASI and DLQI on preferences

Subgroup analyses co-ordinate to gender revealed that men were more concerned almost the probability of 50% and ninety% improvement than women (50% comeback: RIS = 9.5 vs. half-dozen.9, p = 0.008; xc% improvement: RIS = 15.4 vs. 12.1, p = 0.002, Fig 2A). According to regression analyses these results were contained of historic period, partnership, working status, PASI and DLQI (50% improvement: β = -0.191, p = 0.011; ninety% improvement: β = -0.197, p = 0.009, Tabular array 4). Furthermore, models adjusted for these factors showed that women attached greater value to treatment frequency than men (β = 0.161, p = 0.035, Tabular array v).

Fig 2. Impact of gender, age, partnership and working condition on patients' preferences.

(A) Men attached higher value to the probability of 50% and xc% improvement than women. (B) Probability of 50% and 90% improvement, time until response and treatment frequency became less important with increasing age whereas probability of astringent AE and probability of ACR 20 response gained relevance. (C) Participants without a partner placed greater importance on the probability of 50% improvement while respondents with a partner valued the probability of ACR 20 response higher. (D) Compared to not-working participants, full-time working participants set higher priority to time until response, treatment location, and treatment frequency. The probability of 90% improvement was more of import for full-time working than for role-time working participants. Role-time working participants considered the delivery method more of import than non-working participants. Differences in RIS were tested for significance with ANOVA (A, C), 2-tailed t-examination (B) or Bonferroni mail-hoc tests (D). Bars: Means with standard deviations (A, C, D) or Pearson's Correlations (B). RIS: Relative Importance Scores. * p≤0.05, ** p≤0.01.

https://doi.org/10.1371/periodical.pone.0129120.g002

Older participants judged the probability of 50% and 90% improvement less of import than younger ones (50% improvement: PC = -0.161, p = 0.022; 90% comeback: PC = -0.155, p = 0.028, Fig 2B), findings substantiated in adjusted regression models (fifty% comeback: β = -0.219, p = 0.017; 90% improvement: β = -0.264, p = 0.004, Table 4). Withal, older participants worried more virtually severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). Co-ordinate to bivariate analyses, ACR 20 response appeared more than relevant (PC = 0.150, p = 0.035) merely fourth dimension until response (PC = -0.195, p = 0.006) and treatment frequency (PC = -0.146, p = 0.039) less relevant with increasing age (Fig 2B).

Participants living without a partner were more interested in 50% comeback than those with a partner (RIS = 10.1 vs. seven.3, p = 0.015, Fig 2C; β = 0.146, p = 0.044, Tabular array four). However, they were less concerned near ACR twenty response (RIS = 5.0 vs. 6.9; p = 0.004, β = -0.196, p = 0.008).

Monthly household income had no statistically significant affect on preferences, just preferences were influenced by working status (Fig 2D, Table five). Probability of xc% improvement was more important for participants working total-fourth dimension compared to those working part-fourth dimension (RIS = xiv.viii vs. 10.7, p = 0.033). Furthermore, participants with a full-fourth dimension job were more than interested in time until response (RIS = three.4 vs. 5.ii, p = 0.042), treatment location (RIS = seven.2 vs. 9.4, p = 0.026; β = -0.187, p = 0.051) and treatment frequency (RIS = seven.0 vs. 9.seven, p = 0.018; β = 0.192, p = 0.042) than non-working participants. Participants working part-time were more than concerned almost the commitment method than those without work (RIS = 7.ii vs. ten.0, p = 0.016).

Treatment duration became more important with rising PASI (PC = 0.160, p = 0.024, Fig 3A) and ascent DLQI (PC = 0.175, p = 0.013, Fig 3B; β = 0.147, p = 0.066, Table 5). Unexpectedly, the RIS for probability of 50% improvement was negatively correlated with DLQI (PC = -0.158, p = 0.026, Fig 3B), indicating that participants with higher affliction-related quality of life impartment were less interested in reduction of their psoriasis past half. This finding was confirmed in multivariate regression models (β = -0.168, p = 0.031, Table 4).

Fig 3. Touch on of PASI and DLQI on Relative Importance Scores (RIS).

With increasing PASI (A) and increasing DLQI (B), participants set up greater value on treatment duration. The college the DLQI score, the less importance was fastened to probability of 50% improvement. Differences in RIS were tested for significance with 2-tailed t-tests. Confined: Pearson's Correlations. * p≤0.05.

https://doi.org/10.1371/journal.pone.0129120.g003

Discussion

In our written report we practical a method closely resembling clinical conclusion-making for the identification of patients' preferences for biologicals. Attributes and attribute levels reflected characteristics of biologicals canonical for psoriasis in Frg equally accurately as possible in society to create choice scenarios shut to reality. We show that participants attach the greatest importance to abstention of severe AE, in line with CA from Seston et al., according to which psoriasis patients were willing to trade fourth dimension until response for a reduced take chances of severe AE, peculiarly pare cancer and liver damage [16].

We previously performed CA to assess patients' preferences for all handling options currently available for psoriasis [18]. In these experiments patients prioritized process attributes over event. The attribute regarded as virtually important was treatment location, probably considering participants were confronted with the pick of a iii-calendar week hospitalization for treatment with dithranol, which they disliked [eighteen]. Under the prerequisite of an outpatient setting and given the overall convenient treatment process associated with biologicals, participants care only moderately well-nigh the treatment process. Regarding the delivery method, our office-worth utilities indicated than an injection pen was near preferred, followed by subcutaneous syringes, a finding well in accordance with other studies (e.k., [27]).

The relevance attributed to AE can be largely influenced by the examples given, considering patients tend to imagine these conditions and emphasize them during their decision-making, a phenomenon called the framing issue [28]. In our previous study comparing preferences for all treatment modalities, utilities for AE were assessed without giving specific examples, since none of them could have applied to all options at in one case, and RIS for AE-related attributes were low. Here nosotros included examples of several of import mild and astringent AE of biologicals. As the corporeality of data had to exist limited, it was incommunicable to mention each potential AE. In improver, our study does not permit conclusions on how the dissimilar kinds of AE can influence preferences. The perception of rare AE tin can vary immensely depending on how they are presented to the patients. When weighing AE against efficacy, it has to be taken into account that the mean PASI of our participants was relatively low. Thanks to their really good illness control, participants might have focused more than on AE than on clearing.

Regarding efficacy, we assessed utilities of 50% and 90% comeback instead of PASI 75 response charge per unit, which is the about common master endpoint of clinical trials. Beginning, 50% and xc% improvement is easier to imagine for study participants than PASI 75 response. Second, 90% improvement rates of currently available biologicals, roughly reflecting PASI 90 responses, differ stronger than their PASI 75 response rates. Third, we wanted to examine whether 50% improvement is even so a worthwhile treatment goal for patients. Not surprisingly, probability of ninety% improvement was identified every bit the second most important attribute. Efficacy is a key predictor of satisfaction with antipsoriatic medications [12,29]. High prioritization of 90% improvement may indicate that in the era of biologicals patients' expectations are rising towards (nearly) complete clearance. However, participants still valued l% comeback.

When stratifying the RIS for gender, men put higher emphasis on treatment efficiency. This result is surprising, considering that women commonly attach greater importance to advent [thirty] and suffer more than from their psoriasis than men, both mentally and physically [31].

Older study participants were willing to trade efficacy and rapidity of response for safety, corresponding to our previous observations [18]. Indeed, older patients accept a higher run a risk of concomitant diseases and AE from medication [32,33]. Therefore, they might be unwilling to have additional risks of systemic antipsoriatic treatments.

Participants living without a partner valued fifty% improvement higher, possibly due to expectations from society and potential partners [18]. However, they were less interested in ACR xx response. The prevalence of psoriatic arthritis rises with increasing age and duration of psoriasis. Participants without a partner were in average younger than those with a partner (mean historic period: 46.9 vs. 53.iii years) but the difference in utilities of ACR 20 response was all the same statistically significant in multivariate models controlling for age.

Participants working full-time put emphasis on a treatment well compatible with work, i.eastward., on high probability of xc% improvement, rapid onset of action, depression treatment frequency, and a convenient treatment location. Psoriasis can substantially impair piece of work productivity, [34,35] and working patients might feel pressure to reduce absence. The subgroup of participants who were not working comprised homemakers, unemployed and retired participants. It is well conceivable that preferences of homemakers and retired persons differ from those of unemployed patients. Accordant analyses were incommunicable here due to the study design and the limited accomplice size just will exist interesting to perform in hereafter larger-scale studies.

The written report accomplice was heterogeneous with regard to PASI and DLQI and the hateful PASI was relatively depression, but these parameters were indicative of illness command and not of global disease severity, since virtually all participants received treatment at the fourth dimension of written report participation. Participants with higher PASI and higher DLQI were specially interested in a time-saving treatment.

A limitation of our report is that it just comprised patients with moderate-to-severe psoriasis treated at a German University Hospital. Conspicuously, our findings will accept to be verified in larger cohorts and in a multi-centric setting. Moreover, it is likely that preferences can be influenced by further factors such as comorbidities and handling experience. For instance, patients with psoriatic arthritis are more interested in ACR 20 response than others (Schaarschmidt et al., manuscript in training). 46% of the participants had experience with biologicals, but all were candidates for these medications and may be confronted with handling decisions involving biologicals.

A major limitation of conjoint analysis is that the discrete choice experiments are theoretical and actual patients may cull bodily medications differently. Moreover, boilerplate preferences presented here do not allow direct conclusions for each individual. Clearly, treatment decisions for a detail patient are based on his or her individual preferences. Nonetheless, when starting to talk over treatment options with an individual, it is extremely helpful for physicians to know what most patients are interested in and concerned about and how preferences may be systematically influenced by sociodemographic and illness-related characteristics. Based on this cognition, physicians should work out the preferences, needs and concerns of each individual patient and integrate them into therapeutic decisions in guild to optimize treatment satisfaction, adherence and outcome.

Acknowledgments

We thank the physicians and nursing staff of the Department of Dermatology, University Medical Centre Mannheim, for support with participant recruitment.

Author Contributions

Conceived and designed the experiments: CK MLS AS RH SG WKP. Performed the experiments: CK MLS AS WKP. Analyzed the data: CK MLS RH WKP. Wrote the paper: CK MLS AS RH SG WKP.

References

1. 1. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc. 2004; 9: 140–147. pmid:15083781
   • View Article
   • PubMed/NCBI
   • Google Scholar
2. ii. Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schaefer I, et al. Fourth dimension needed for treatment is the major predictor of quality of life in psoriasis. Dermatology. 2010; 221: 154–159. pmid:20558972
   • View Article
   • PubMed/NCBI
   • Google Scholar
3. 3. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti South, Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006; 155: 729–736. pmid:16965422
   • View Article
   • PubMed/NCBI
   • Google Scholar
4. iv. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the direction of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58: 826–850. pmid:18423260
   • View Article
   • PubMed/NCBI
   • Google Scholar
5. v. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, Wang Y, et al. Efficacy and safety of ustekinumab, a human being interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-bullheaded, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665–1674. pmid:18486739
   • View Article
   • PubMed/NCBI
   • Google Scholar
6. 6. Reich K, Brunt AD, Eaton JN, Hawkins NS. Efficacy of biologics in the handling of moderate to severe psoriasis: a network meta-assay of randomized controlled trials. Br J Dermatol. 2012; 166: 179–188. pmid:21910698
   • View Article
   • PubMed/NCBI
   • Google Scholar
7. seven. Gniadecki R, Blindside B, Bryld LE, Iversen L, Lasthein Southward, Skov L. Comparison of long-term drug survival and safe of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015; 172: 244–252. pmid:25132294
   • View Article
   • PubMed/NCBI
   • Google Scholar
8. viii. Nast A, Sporbeck B, Rosumeck S, Pathirana D, Jacobs A, Werner RN, et al. Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of activeness. J Invest Dermatol. 2013; 133: 1963–1970. pmid:23426133
   • View Commodity
   • PubMed/NCBI
   • Google Scholar
9. nine. Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012; 71: 319–326. pmid:21803753
   • View Commodity
   • PubMed/NCBI
   • Google Scholar
10. ten. McInnes IB, Kavanaugh A, Gottlieb AB, Puig 50, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: i year results of the stage 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013; 382: 780–789. pmid:23769296
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
11. 11. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011; 222: 363–374. pmid:21757881
    • View Article
    • PubMed/NCBI
    • Google Scholar
12. 12. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM. Satisfaction with treatment amidst patients with psoriasis: a web-based survey study. Br J Dermatol. 2013; 169: 398–405. pmid:23565643
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
13. 13. Opmeer BC, Heydendael VM, deBorgie CA, Spuls PI, Bossuyt PM, Bos JD, et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol. 2007; threescore: 696–703. pmid:17573985
    • View Article
    • PubMed/NCBI
    • Google Scholar
14. fourteen. Kjaer T, Bech Thou, Gyrd-Hansen D, Hart-Hansen M. Ordering event and cost sensitivity in discrete option experiments: need nosotros worry? Wellness Econ. 2006; fifteen: 1217–1228. pmid:16786550
    • View Article
    • PubMed/NCBI
    • Google Scholar
15. 15. Ashcroft DM, Seston E, Griffiths CE. Trade-offs betwixt the benefits and risks of drug treatment for psoriasis: a discrete selection experiment with U.K. dermatologists. Br J Dermatol. 2006; 155: 1236–1241. pmid:17107395
    • View Article
    • PubMed/NCBI
    • Google Scholar
16. 16. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete selection experiment with patients with psoriasis. Arch Dermatol. 2007; 143: 1175–1179. pmid:17875880
    • View Article
    • PubMed/NCBI
    • Google Scholar
17. 17. Umar North, Yamamoto Due south, Loerbroks A, Terris D. Elicitation and use of patients' preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol. 2012; 92: 341–346. pmid:22278662
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
18. eighteen. Schaarschmidt ML, Schmieder A, Umar N, Terris D, Goebeler Thou, Goerdt South, et al. Patient preferences for psoriasis treatments: process characteristics tin outweigh outcome attributes. Arch Dermatol. 2011; 147: 1285–1294. pmid:22106115
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
19. 19. Schaarschmidt ML, Umar N, Schmieder A, Terris D, Goebeler K, Goerdt Southward, et al. Patient preferences for psoriasis treatments: bear on of treatment experience. J Eur Acad Dermatol Venereol. 2013; 27: 187–198. pmid:22225546
    • View Article
    • PubMed/NCBI
    • Google Scholar
20. twenty. Schmieder A, Schaarschmidt ML, Umar Northward, Terris DD, Goebeler M, Goerdt Southward, et al. Comorbidities significantly touch on patients' preferences for psoriasis treatments. J Am Acad Dermatol. 2012; 67: 363–372. pmid:22015150
    • View Article
    • PubMed/NCBI
    • Google Scholar
21. 21. Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schöllgen I, Terris DD. Matching physicians' treatment recommendations to patients' treatment preferences is associated with comeback in treatment satisfaction. J Eur Acad Dermatol Venereol. 2013; 27: 763–770. pmid:22631875
    • View Article
    • PubMed/NCBI
    • Google Scholar
22. 22. Taylor West, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: evolution of new criteria from a large international study. Arthritis Rheum. 2006; 54: 2665–2673. pmid:16871531
    • View Article
    • PubMed/NCBI
    • Google Scholar
23. 23. Reich G, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Comparative effects of biological therapies on the severity of pare symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin. 2008; 24: 1237–1254. pmid:18355421
    • View Article
    • PubMed/NCBI
    • Google Scholar
24. 24. Schmitt J, Zhang Z, Wozel M, Meurer Chiliad, Kirch Due west. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-astringent psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol. 2008; 159: 513–526. pmid:18627372
    • View Article
    • PubMed/NCBI
    • Google Scholar
25. 25. van Lumig PP, Driessen RJ, Berends MA, Boezeman JB, van de Kerkhof PC, de Jong EM. Safety of handling with biologics for psoriasis in daily practice: 5-yr data. J Eur Acad Dermatol Venereol. 2012; 26: 283–291. pmid:21435026
    • View Article
    • PubMed/NCBI
    • Google Scholar
26. 26. Nast A, Boehncke WH, Mrowietz U, Ockenfels HM, Philipp Southward, Reich K, et al. S3—Guidelines on the handling of psoriasis vulgaris (English version). Update. J Dtsch Dermatol Ges. 2012; 10 Suppl two: S1–95. pmid:22386073
    • View Article
    • PubMed/NCBI
    • Google Scholar
27. 27. Paul C, Stalder JF, Thaci D, Vincendon P, Brault Y, Kielar D, et al. Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept commitment systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2012; 26: 448–455. pmid:21557778
    • View Article
    • PubMed/NCBI
    • Google Scholar
28. 28. Gong J, Zhang Y, Yang Z, Huang Y, Feng J, Zhang Due west. The framing result in medical decision-making: a review of the literature. Psychol Health Med. 2013; 18: 645–653. pmid:23387993
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
29. 29. Finlay AY, Ortonne JP. Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy. J Cutan Med Surg. 2004; 8: 310–320. pmid:15868312
    • View Article
    • PubMed/NCBI
    • Google Scholar
30. 30. Harris DL, Carr AT. Prevalence of concern most physical appearance in the general population. Br J Plast Surg. 2001; 54: 223–226. pmid:11254414
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
31. 31. Grozdev I, Kast D, Cao L, Carlson D, Pujari P, Schmotzer B, et al. Physical and mental touch of psoriasis severity as measured by the meaty Brusque Form-12 Health Survey (SF-12) quality of life tool. J Invest Dermatol. 2012; 132: 1111–1116. pmid:22205305
    • View Article
    • PubMed/NCBI
    • Google Scholar
32. 32. Hovstadius B, Hovstadius Chiliad, Astrand B, Petersson K. Increasing polypharmacy—an private-based study of the Swedish population 2005–2008. BMC Clin Pharmacol. 2010; 10: 16. pmid:21122160
    • View Commodity
    • PubMed/NCBI
    • Google Scholar
33. 33. Boyd CM, Ritchie CS, Tipton EF, Studenski SA, Wieland D. From Bedside to Bench: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Comorbidity and Multiple Morbidity in Older Adults. Aging Clin Exp Research. 2008; 20: 181–188. pmid:18594183
    • View Article
    • PubMed/NCBI
    • Google Scholar
34. 34. Armstrong AW, Robertson Advert, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction amidst patients with psoriasis and psoriatic arthritis in the U.s.a.: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol. 2013; 149: 1180–1185. pmid:23945732
    • View Article
    • PubMed/NCBI
    • Google Scholar
35. 35. Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, et al. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity harm for patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012; 66: e67–76. pmid:21616560
    • View Commodity
    • PubMed/NCBI
    • Google Scholar

brownyousaity45.blogspot.com

Source: https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0129120

Share this post